TABLE 2.
ID | Lymphocyte Transformation Test |
Piperacillin ELIspot |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Control | Piperacillin |
Tetanus Toxoid | IFN-γ, 2 mM | IL-13, 2 mM | |||||||
0.06 mM | 0.13 mM | 0.25 mM | 0.5 mM | 1 mM | 2 mM | 4 mM | |||||
cpm | |||||||||||
Piperacillin-hypersensitive patients | |||||||||||
1 | 2957 | <2a | <2 | 2.3 | 2.8 | 8.3 | 6.3 | 7.0 | 23.4 | +++b | ++ |
2 | 804 | 2.1 | 2.8 | 6.5 | 5.9 | 5.7 | 4.4 | 1.8 | 24.0 | ++ | ++ |
3 | 2138 | <2 | <2 | <2 | <2 | 4.8 | 3.1 | 2.6 | 22.1 | +++ | ++ |
4 | 1787 | <2 | 2.4 | 3.6 | 6.9 | 6.7 | 6.8 | 4.5 | 13 | + | + |
5 | 1685 | 30.0 | 39.8 | 47.2 | 62.5 | 60.0 | 55.0 | 41.1 | 35.4 | +++ | +++ |
6 | 1436 | 5.6 | 11.5 | 16.0 | 20.1 | 31.4 | 26.7 | 28.1 | 16.0 | ++ | + |
7 | 1222 | <2 | <2 | <2 | 2.8 | 3.7 | 6.3 | 6.6 | 27.3 | ++ | − |
8 | 1017 | <2 | <2 | <2 | 2.5 | 7.7 | 5.9 | 10.4 | 47 | ++ | − |
Piperacillin-tolerant patients | |||||||||||
1 | 542 | <2 | <2 | <2 | <2 | <2 | <2 | <2 | 21.8 | − | − |
2 | 301 | <2 | <2 | <2 | <2 | <2 | <2 | <2 | 11.1 | − | − |
3 | 980 | <2 | <2 | <2 | <2 | <2 | <2 | <2 | 8.9 | − | − |
4 | 163 | <2 | <2 | <2 | 2.2 | <2 | <2 | <2 | 3.2 | − | − |
5 | 233 | <2 | <2 | <2 | <2 | <2 | <2 | <2 | 28.1 | − | − |
Data presented as stimulation index (cpm in test incubations/cpm in control incubations).
Spot-forming cells after piperacillin (2 mM) treatment, with control subtracted: −, <10; +, 10–30; ++, 30–100; +++, >100.